Biological
EBV mRNA vaccine
EBV mRNA vaccine is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph early_phase_1
1
33%
Ph not_applicable
1
33%
Ph phase_1
1
33%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Not yet recruiting2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Early Phase 11 (33.3%)
Phase 11 (33.3%)
N/A1 (33.3%)
Trials by Status
active_not_recruiting133%
not_yet_recruiting267%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingearly_phase_1
Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine
NCT07563023
not_yet_recruitingnot_applicable
The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV)
NCT07101536
active_not_recruitingphase_1
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors
NCT05714748
Clinical Trials (3)
Showing 3 of 3 trials
NCT07563023Early Phase 1
Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine
NCT07101536Not Applicable
The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV)
NCT05714748Phase 1
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3